US EditionPublished • loading... • Updated
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents aims for cash-flow breakeven in H2 2026 amid FDA progress on DrugSorb-ATR and 4% revenue growth to $37.1 million in 2025, with 71% gross margins.
- On Wednesday, March 25, 2026, CytoSorbents Corporation reported 2025 revenue of $37.1 million, up 4% year-over-year, with net loss improving to $8.2 million from $20.7 million in 2024.
- To optimize operations, CytoSorbents implemented a strategic workforce and cost reduction program in Q4 2025, reducing headcount by 10% while lowering expenses and realigning production spend.
- Full-Year gross margins reached 71% in 2025, while the company secured an additional $2.5 million in liquidity through a November 2025 amendment to its credit facility.
- CytoSorbents continues interactive discussions with the U.S. Food and Drug Administration to determine content and timing for a new De Novo submission for DrugSorb-ATR.
- Chief Executive Officer Dr. Phillip Chan stated the company anticipates achieving cash flow breakeven in the second half of 2026, supported by a lower cost structure and clinical momentum.
Insights by Ground AI
28 Articles
28 Articles
Bennington Banner+26 Reposted by 26 other sources
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross marginsEnhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in NovemberImplemented Strategic Workforce and Cost Reduction Program in Q4 to Accelerate Timing to…
Coverage Details
Total News Sources28
Leaning Left2Leaning Right4Center9Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
13%
C 60%
R 27%
Factuality
To view factuality data please Upgrade to Premium
